D.H. Yoon

University of Ulsan, Ulsan, Ulsan, South Korea

Are you D.H. Yoon?

Claim your profile

Publications (389)706.07 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) has been shown to improve the rates of successful peripheral blood stem cell (PBSC) mobilization in patients with malignant lymphoma or multiple myeloma (MM) who experienced prior failure of PBSC mobilization. We evaluated the mobilization results of re-mobilization using plerixafor and G-CSF in insufficiently mobilizing patients. Forty-four patients with lymphoma (n = 29) or MM (n = 15) were included in the study. The median age was 50 (range, 24-64) years. Previous mobilization regimens were chemotherapy with G-CSF (n = 28), including cyclophosphamide with G-CSF (n = 15), and G-CSF only (n = 16). All patients with lymphoma achieved at least partial response (PR) before the mobilization, including 13 complete responses (CRs). Eleven patients with MM achieved at least PR and four patients with MM were in stable disease before mobilization. The median number of apheresis was 3 (range, 1-6). The median yield of PBSC collections was 3.41 (0.13-38.11) × 10(6) CD34(+) cells/kg. Thirty-four (77.3 %) patients had successful collections defined as at least 2 × 10(6) CD34(+) cells/kg. The rate of successful collections was not different between the two underlying diseases (79.3 % in lymphoma and 73.3 % in MM). Of the entire cohort, 38 (86.4 %) of patients went on to receive an autologous transplant. Previous long-term use of high-risk drugs (>4 cycles use of alkylating agents, platinum-containing agents, or thalidomide) (HR 10.8, 95 % CI 1.1-110.0, P = 0.043) and low platelet count (<100 × 10(9)/L) 1 day before the first apheresis (HR 27.9, 95 % CI 2.9-273.7, P = 0.004) were independent prognostic factors for predicting failure of PBSC re-mobilization using plerixafor and G-CSF. In conclusion, re-mobilization using plerixafor and G-CSF showed a success rate of 77.3 % in patients with lymphoma or MM who experienced prior failure of PBSC mobilization, and the majority of them underwent autologous transplant. Therefore, plerixafor-based re-mobilization was an effective method in poor mobilizers.
    No preview · Article · Jan 2016 · Annals of Hematology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Programmed cell death protein-1 (PD-1) inhibitor may be therapeutic in patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). This study examined the prognostic significance of PD-1 and two PD-1 ligands (PD-L1 and PD-L2) in uniformly treated cHL. Diagnostic tissues from 109 cHL patients treated with a doxorubicin, bleomycin, vinblastine, and dacarbazine regimen were evaluated retrospectively by immunohistochemical analysis of PD-L1, PD-L2, and PD-1 expressions. The median follow-up time was 4.91 years (range, 0.17-17.33 years). Thirteen patients (11 %) expressed PD-1 protein in the peritumoral microenvironment, which was associated with poor overall survival (OS) (P = 0.017). PD-L1 or PD-L2 expression was not associated with OS. There was no correlation between PD-L1 and PD-1 expression or between PD-L2 and PD-1 expression. Multivariate analysis identified PD-1 protein as an independent prognostic factor for OS (P = 0.019). Subgroup analysis according to the Ann Arbor stage of cHL showed that PD-1 protein expression had a prognostic value in limited-stage cHL (P = 0.048). PD-1 is an independent prognostic factor in cHL and may allow the identification of a subgroup of patients with limited-stage cHL who require more intensive therapy and who may benefit from anti-PD-1 agents.
    No preview · Article · Dec 2015 · Tumor Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lu3Al5O12:Ce3+ phosphor ceramic plates can be combined with blue chips to produce white light emitting diodes (WLEDs). Lu3Al5O12:Ce3+ was synthesized using a solid state reaction and was sintered under a reduction atmosphere. The phosphor ceramic plates exhibited good thermal effects with a Lu3Al5O12:Ce3+ phosphor ceramic plates of varying thickness. Lu3Al5O12:Ce3+ phosphor ceramic plates also exhibited quenching properties at extraordinarily high temperatures. We suggest that Lu3Al5O12:Ce3+ phosphor ceramic plates can be a candidate for next-generation high-power LEDs.
    No preview · Article · Dec 2015 · Materials Letters
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CD99 signaling is crucial to a diverse range of biological functions including survival and proliferation. CD99 engagement is reported to augment activator protein-1 (AP-1) activity through mitogen-activated protein (MAP) kinase pathways in a T-lymphoblastic lymphoma cell line Jurkat and in breast cancer cell lines. In this study, we report that CD99 differentially regulated AP-1 activity in the human myeloma cell line RPMI8226. CD99 was highly expressed and the CD99 engagement led to activation of the MAP kinases, but suppressed AP-1 activity by inducing the expression of basic leucine zipper transcription factor, ATF-like (BATF), a negative regulator of AP-1 in RPMI8226 cells. By contrast, engagement of CD99 enhanced AP-1 activity and did not change the BATF expression in Jurkat cells. CD99 engagement reduced the proliferation of RPMI8226 cells and expression of cyclin 1 and 3. Overall, these results suggest novel CD99 functions in RPMI8226 cells.
    Preview · Article · Nov 2015 · Immune Network
  • [Show abstract] [Hide abstract]
    ABSTRACT: Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. We conducted this phase II trial to assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130mg/m(2) on day 1, and prednisone 100mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range 27-74) years. There were 7 complete response (20.6%) and 15 partial response (44.1%) (Overall response rate 64.7%). No treatment related deaths occurred. The median progression free survival was 14.2 months (95% CI, 2.1-26.3 months). 3 year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule, showed moderate clinical activity and considerable in very few selected patients. (NCT01068392).
    No preview · Article · Sep 2015 · Leukemia & lymphoma
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/aims: The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 10(9)/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.
    Preview · Article · Sep 2015 · The Korean Journal of Internal Medicine
  • Hyewon Ryu · S. Kim · K. Lee · C. Suh · D.H. Yoon

    No preview · Article · Sep 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lessons learned: Addition of cetuximab may affect tolerability and, in turn, affect eventual outcomes.The incidence of prior human papillomavirus infection has emerged as an important variable that can confound trials enrolling patients with oropharyngeal cancer. Background: We investigated the efficacy of cetuximab when added to induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck squamous cell carcinoma. Methods: Patients were randomized to receive three cycles of docetaxel and cisplatin (TP regimen) with or without cetuximab (TP plus cetuximab [CTP] vs. TP) as induction chemotherapy. Patients in the CTP arm received CCRT with cetuximab and cisplatin, whereas patients in the TP arm received cisplatin alone. The primary endpoint was the objective response rate (ORR) after induction chemotherapy. Results: Overall, 92 patients were enrolled. The ORRs for induction chemotherapy in the CTP and TP arms were not different (81% vs. 82%). Adding cetuximab lowered the completion rate of induction chemotherapy and CCRT and resulted in more frequent dose reductions of the induction chemotherapy, although this did not reach statistical significance. In the CTP and TP arms, respectively, the 3-year progression-free survival (PFS) rates were 70% and 56% (p = .359), and the overall survival (OS) rates were 88% and 74% (p = .313). When limited to patients who completed induction chemotherapy, 3-year PFS rates of 78% and 59% (p = .085) and OS rates of 94% and 73% (p = .045) were observed in the CTP and TP arms, respectively. Conclusion: Adding cetuximab to sequential treatment did not increase the treatment efficacy and resulted in greater toxicity. In the intent-to-treat population, neither PFS nor OS was improved by the addition of cetuximab to sequential treatment; however, a suggestion of improved survival outcomes was observed in patients completing cetuximab-containing induction chemotherapy.
    Preview · Article · Aug 2015 · The Oncologist
  • [Show abstract] [Hide abstract]
    ABSTRACT: We compared the outcomes of higher-risk diffuse large B cell lymphoma (DLBCL) patients who were treated with either up-front autologous stem cell transplantation (ASCT) or with salvage chemotherapy followed by delayed ASCT after relapse. Data from 122 DLBCL patients who underwent ASCT as up-front or salvage treatment were analyzed. The 3-year overall survival (OS) rates in DLBCL patients who underwent up-front ASCT or delayed ASCT were 76.6% and 60.9%, respectively (P = 0.017). In a subgroup analysis of patients with a high-intermediate/high-risk age-adjusted International Prognostic Index, achievement of complete remission (CR) translated into an improved OS in the up-front ASCT group, while patients who achieved partial remission (PR) showed a similar OS in both groups. The up-front ASCT group had improved OS in patients aged <50 years or with a good performance status, while the OS of both groups was similar in patients aged ≥60 years or with a poor performance status. When the OS outcome is analyzed by the number of factors (no CR during R-CHOP induction chemotherapy, age ≥ 50 years, and performance status ≥ 2), the 3-year OS rates of patients with zero or one, two, and three clinical factors were 80.2%, 51.6%, and 0%, respectively (P < 0.001). In conclusion, in higher-risk DLBCL patients, induction chemotherapy followed by up-front ASCT may have a survival benefit compared with induction chemotherapy alone in highly selected patients who have achieved a CR, who are aged <50 years, and who have a good performance status at diagnosis. Copyright © 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.
    No preview · Article · Aug 2015 · Experimental hematology
  • Y. H. Song · M. J. Lee · Y. L. Song · G. S. Han · H. S. Jung · D. H. Yoon
    [Show abstract] [Hide abstract]
    ABSTRACT: A facile synthetic technique for producing high-quality red-emitting Sr2Si5N8 : Eu2+ phosphor was successfully prepared at 1600 C for 5 hours under an unpressurized 5%H2/95%N2 atmosphere. The prepared Sr2Si5N8 : Eu2+ phosphor showed broadband emission spectra as well as higher emission intensity than the conventional Sr2Si5N8 : Eu2+ phosphor. The phosphor-converted LED with Sr2Si5N8 : Eu2+ by facile synthetic route showed an increase of quantum efficiency of 10% with a high color rendering index value (>90). Therefore, we expect this synthetic technique to be a candidate for enhancing the photoluminescence properties of nitride phosphor.
    No preview · Article · Aug 2015 · Science of Advanced Materials
  • [Show abstract] [Hide abstract]
    ABSTRACT: Even though local stage (Ann Arbor stage I/II) marginal zone lymphoma (MZL) is well controlled with local treatment-based therapy, no data exist on the role of additional chemotherapy after local treatment for stage I/II MZL. Patients with biopsy-confirmed Ann Arbor stage I/II MZL (n = 210) were included for analysis in this study. Of these, 180 patients (85.7 %) were stage I and 30 (14.3 %) were stage II. Most patients (n = 182, 86.7 %) were treated with a local modality including radiation therapy or surgery and 28 (13.3 %) received additional systemic chemotherapy after local treatment. The overall response rate was 98.3 % (95 % CI 96-100 %), with 187 complete responses and 20 partial responses. In the local treatment group, the mean progression-free survival (PFS) was 147.4 months (95 % CI 126.7-168.1 months) and the overall survival (OS) was 188.2 months (95 % CI 178.8-197.7 months). In the additional chemotherapy group, the mean PFS was 103.4 months (95 % CI 84.9-121.9 months) and the OS was 137.3 months (95 % CI 127.9-146.7 months). There was no difference between the two groups in OS (p = 0.836) and PFS (p = 0.695). Local stage MZL has a good clinical course and is well controlled with a local treatment modality without additional chemotherapy.
    No preview · Article · Jul 2015 · International journal of hematology
  • Hee Sang Hwang · Dok Hyun Yoon · Cheolwon Suh · Jooryung Huh
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity was recently reported to confer a survival advantage in diffuse large B cell lymphoma (DLBCL) among Western populations. Given ethnic differences, previous studies recommended a revision of the WHO classification of obesity for Asians. We investigated the prognostic impact of body mass index (BMI) using modified WHO criteria in a retrospective cohort of 562 Korean patients with DLBCL. Patients were categorized into five groups according to BMI: 26 (4.6 %) as underweight (<18.5 kg/m(2)), 230 (40.9 %) as normal weight (18.5-22.9 kg/m(2)), 129 (23.0 %) as overweight (23.0-24.9 kg/m(2)), 160 (28.5 %) as obese (25.0-29.9 kg/m(2)), and 17 (3.0 %) as severely obese (≥30 kg/m(2)). As BMI increased, the relative hazard ratio (HR) decreased sharply, reaching the lowest value in the overweight group, and then rose again in the obese and severely obese. On univariate analysis, both overall survival (OS) and progression-free survival (PFS) were best in the overweight group, followed by normal > obese > severely obese > underweight groups. Multivariate analysis showed a significantly shorter survival in the underweight (OS: HR 2.90, 95 % confidence interval (CI) 1.35-6.19, P = 0.006; PFS: HR 3.08, 95 % CI 1.55-6.09, P = 0.001) and severely obese groups (OS: HR 2.93, 95 % CI 1.08-7.95, P = 0.035; PFS: HR 2.59, 95 % CI 1.06-6.36, P = 0.038). We show that being underweight or, contrary to findings in Western patients, being severely obese has a deleterious prognostic impact in DLBCL in Koreans. Revising the BMI criterion that defines obesity according to the patient's ethnic differences could therefore better delineate DLBCL risk groups in Asian patients.
    No preview · Article · Jul 2015 · Annals of Hematology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Limited data exist on up-front autologous stem cell transplantation (ASCT) in extranodal natural killer/T-cell lymphoma (ENKTL). Sixty-two patients (male, N = 43; female, N = 19) with newly diagnosed ENKTL who underwent up-front ASCT following primary therapy were identified. Poor-risk characteristics included advanced stage (50%), high-intermediate to high risk international prognostic index (25.8%), and group 3 to 4 of NK/T-cell lymphoma prognostic index (NKPI, 67.7%). Pre-transplant responses included complete remission (CR) in 61.3% and partial remission in 38.7% of patients, and final post-transplantation response included CR in 78.3%. Early progression occurred in 12.9%. At a median follow-up of 43.3 months (3.7-114.6 months), 3-year progression-free survival (PFS) was 52.4%, and 3-year overall survival (OS) was 60.0%. Patients with limited disease had significantly better 3-year PFS (64.5% vs. 40.1%, P = 0.017) and OS (67.6% vs. 52.3%, P = 0.048) than those with advanced disease. Multivariate analysis showed NKPI and pre-transplant response were independent prognostic factors influencing survival, particularly NKPI in limited disease and pre-transplant response in advanced disease. Radiotherapy was an independent factor for reduced progression and survival in patients with limited disease, but anthracycline-based chemotherapy was poor prognostic factor for progression in patients with advanced disease. Up-front ASCT is an active treatment in ENKTL patients responding to primary therapy. Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
    No preview · Article · May 2015 · Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to examine the prognostic significance of insulin-like growth factor-1 receptor (IGF-1R) expression alone and in relation to the expression of the MET- receptor and the MET-homologous receptor RON, in classical Hodgkin's lymphoma (cHL). Tumour samples from patients with cHL (n = 202; median age 37.5 years) were analysed retrospectively for IGF-R1, MET or RON expression by immunohistochemistry using tissue microarrays. The median follow-up time was 3.7 years (range, 0.1-20 years). Twenty-nine patients (14.3%) expressed IGF-1R protein in Hodgkin/Reed-Sternberg (HRS) cells, which was associated with a better overall survival (OS) (P = 0.036). IGF-1R expression was closely associated with MET receptor expression and low level of lactate dehydrogenase. In patients with cHL receiving doxorubicin, bleomycin, vinblastine and dacarbazine, those expressing IGF-1R showed a trend towards better OS and event-free survival than IGF-1R-negative patients (P = 0.129 and P = 0.115 respectively), but statistical significance was not reached. This study suggests that IGF-1R expression could be associated with better clinical outcome in cHL but is significantly associated with the expression of MET receptor. © 2015 The Authors. International Journal of Experimental Pathology © 2015 International Journal of Experimental Pathology.
    No preview · Article · Apr 2015 · International Journal of Experimental Pathology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC). ACC patients with documented disease progression within the past 12 months were eligible. Patients received oral dovitinib (500 mg once daily for 5 consecutive days followed by a 2-day rest every week) until disease progression or unacceptable toxicities. The primary endpoint was the probability of 4-month progression-free survival (PFS). Metabolic response was evaluated with positron emission tomography (PET)/computed tomography (CT) scans performed at the baseline and after 8 weeks of treatment. Between September 2011 and April 2013, 32 patients with metastatic and/or unresectable ACC were enrolled in this prospective, multicenter trial. The 4-month PFS probability was 80.4%, and the median PFS was 6.0 months (95% confidence interval, 4.4-7.6 months). Tumor shrinkage was observed in 22 patients (68.8%), and 1 patient had a confirmed partial response. The disease control rate was 96.9%. Among 26 patients with PET/CT scans both before and after treatment (at 8 weeks), the metabolic activity of ACC was reduced in 13 patients (50.0%), and 5 patients (19.2%) achieved a metabolic partial response, which was defined as a ≥25% reduction in maximum standardized uptake values. Common grade 3 and 4 adverse events were asthenia (50.0%) and neutropenia (25.0%). Dovitinib shows modest antitumor activity in the treatment of ACC. Cancer 2015. © 2015 American Cancer Society. © 2015 American Cancer Society.
    No preview · Article · Apr 2015 · Cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess, in a randomized, phase 2 trial, the efficacy and safety of chemoradiotherapy with or without induction chemotherapy (ICT) of S1 and oxaliplatin for esophageal cancer. Patients with stage II, III, or IVA esophageal cancer were randomly allocated to either 2 cycles of ICT (oxaliplatin 130 mg/m(2) on day 1 and S1 at 40 mg/m(2) twice daily on days 1-14, every 3 weeks) followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m(2) on days 1 and 21 and S1 30 mg/m(2) twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A), or the same CCRT followed by esophagectomy without ICT (arm B). The primary endpoint was the pathologic complete response (pCR) rate. A total of 97 patients were randomized (arm A/B, 47/50), 70 of whom underwent esophagectomy (arm A/B, 34/36). The intention-to-treat pCR rate was 23.4% (95% confidence interval [CI] 11.2-35.6%) in arm A and 38% (95% CI 24.5% to 51.5%) in arm B. With a median follow-up duration of 30.3 months, the 2-year progression-free survival rate was 58.4% in arm A and 58.6% in arm B, whereas the 2-year overall survival rate was 60.7% and 63.7%, respectively. Grade 3 or 4 thrombocytopenia during CCRT was more common in arm A than in arm B (35.4% vs 4.1%). The relative dose intensity of S1 (89.5% ± 20.6% vs 98.3% ± 5.2%, P=.005) and oxaliplatin (91.4% ± 16.8% vs 99.0% ± 4.2%, P=.007) during CCRT was lower in arm A compared with arm B. Three patients in arm A, compared with none in arm B, died within 90 days after surgery. Combination chemotherapy of S1 and oxaliplatin is an effective chemoradiotherapy regimen to treat esophageal cancer. However, we failed to show that the addition of ICT to the regimen can improve the pCR rate. Copyright © 2015 Elsevier Inc. All rights reserved.
    No preview · Article · Mar 2015 · International journal of radiation oncology, biology, physics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trastuzumab (H)-based chemotherapy has been an active treatment in patients with HER2-positive breast cancer; however, primary and secondary resistance has occurred in patients treated with H alone or in combination with chemotherapy. Biomarkers were searched using tissue microarrays (TMA) in HER2-positive advanced breast cancer patients treated with H and paclitaxel (P) combination chemotherapy between October 2004 and August 2010. Tumor blocks were analyzed for Tau-protein, beta-III tubulin, PTEN, p27, IGF-1R, c-Met, CD44, and MUC4 by immunohistochemical (IHC) analysis. The correlation between IHC status and clinical outcomes, including response rate (RR), progression free survival (PFS), and overall survival (OS), was investigated. With a median follow-up duration of 54.1 months (range, 42.3-72.7 months), 65 patients received H + P chemotherapy. The overall RR was 63 % (95 % CI, 51-75 %), and seven patients (11 %) with high Tau/low PTEN expression showed a significantly lower RR (14 % vs. 69 %; p = 0.008). The odds ratio for a poor response was 13.3 (95 % CI, 1.5-119.0; p = 0.020). In addition, patients with high Tau/low PTEN showed a trend of poor survival in terms of PFS (6.6 months vs. 9.6 months, p = 0.052). Subsequent multivariate analysis showed that high Tau/low PTEN (hazard ratio [HR] 2.40, 95 % CI, 1.06-5.47; p = 0.037) was the poor prognostic factor independently associated with PFS after adjusting for possible confounding factors such as recurrence/metastasis, age, performance status, visceral metastasis, and hormone receptor status. High Tau-protein and low PTEN expression showed a significant association with poor response to H + P chemotherapy in patients with HER2-positive advanced breast cancer.
    No preview · Article · Mar 2015 · Tumor Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mantle cell lymphoma (MCL) has a heterogeneous clinical course. Although most cases show a poor prognosis, a minority has an indolent course. It is difficult to identify indolent MCL cases prospectively. T-cell leukemia/lymphoma protein 1 (TCL1) is expressed by several B cell lymphomas, including MCL. The present study examined the expression of TCL1 and its prognostic relevance for MCL. Clinical data for162 MCL patients were collected. Of these, 144 cases with available tissues for tissue microarray construction and immunostaining were included in the analysis. TCL1 staining was quantified using the Nuclear Quant application with Pannoramic(™) Viewer v. 1.14. High TCL1 expression was defined as moderate to strong nuclear and/or cytoplasmic staining in 40% or more of the cells. High TCL1 expression was observed in 39/144 samples (27.1%). Patients with low TCL1 expression were more likely to present with blastoid/pleomorphic morphology (p=0.010). Low TCL1 expression was associated with significantly shorter overall survival (OS, p =0.006). Multivariate analysis identified low TCL1 expression (p=0.003), high-risk MIPI (p=0.027) and anemia (p=0.018) as adverse prognostic factors. Our study suggests that TCL1 expression profile may have a role in the prediction of overall outcome in MCL patient, and call for prospective studies. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    No preview · Article · Feb 2015 · European Journal Of Haematology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although serum beta-2 microglobulin (B2M) has been suggested as a prognostic factor for mantle cell lymphoma (MCL), additional data are necessary to confirm its role. Between November 2005 and July 2014, a total of 52 patients with MCL were identified from the database of Asan Medical Center, Seoul, Korea. Pretreatment serum B2M information was available in 50 patients (96%). Overall survival (OS) was compared according to the serum B2M level with a cut-off value of 2.5 mg/L. The median MCL international prognostic index (MIPI) score was 5.84 (range 4.72-7.80), and the median biologic MIPI (MIPI-b) score was 6.27 (4.93-8.47). Pretreatment serum B2M was elevated in 30 patients (60%) and was significantly related to advanced stage (p = 0.02) and high MIPI (p = 0.03) and MIPI-b (p = 0.03) scores. With median follow-up duration of 29.8 months (range 0.8-87.0 months), the median OS was 56.2 months [95% confidence interval (CI) 36.6-75.9 months] in all patients, and serum B2M was significantly associated with OS (p = 0.001). In multivariate analyses adjusted for MIPI or MIPI-b scores and rituximab, elevated serum B2M was significantly associated with poor OS (when adjusting MIPI, hazard ratio = 26.4, 95% CI 2.9-241.3, p = 0.004; when adjusting MIPI-b, hazard ratio = 20.1, 95% CI 2.4-170.1, p = 0.006). Thus, pretreatment serum B2M may be an independent and significant prognostic factor in patients with MCL. Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.
    No preview · Article · Feb 2015 · Hematological Oncology
  • M. J. Lee · Y.H. Song · Y.L. Song · G. S. Han · H. S. Jung · D. H. Yoon
    [Show abstract] [Hide abstract]
    ABSTRACT: We demonstrate a simple method of K2SiF6:Mn4+ red phosphor and discuss its promising application in warm-white lighting emitting diodes. The K2SiF6:Mn4+ was synthesized from SiO2 powders through redox reaction in HF/KMnO4 solution. To further increase emission efficiency, KF was introduced in the solution. An intense absorption band in blue and a bright emission in red indicated the phosphor K2SiF6:Mn4+. This phosphor and the synthesis method are expected to be promising candidates for application in white LEDs.
    No preview · Article · Feb 2015 · Materials Letters

Publication Stats

3k Citations
706.07 Total Impact Points

Institutions

  • 2008-2015
    • University of Ulsan
      • • Asan Medical Center
      • • Department of Internal Medicine
      • • College of Medicine
      Ulsan, Ulsan, South Korea
  • 1999-2015
    • Sungkyunkwan University
      • School of Advanced Materials Science and Engineering (AMSE)
      Sŏul, Seoul, South Korea
  • 2014
    • Seoul National University Hospital
      Sŏul, Seoul, South Korea
  • 2009-2014
    • Ulsan University Hospital
      Urusan, Ulsan, South Korea
    • Yeungnam University
      • School of Materials Science and Engineering
      경산시, Gyeongsangbuk-do, South Korea
  • 2009-2013
    • Asan Medical Center
      • • Department of Oncology
      • • Department of Pathology
      Sŏul, Seoul, South Korea
  • 2006-2013
    • Kyungpook National University
      • Animal Science
      Daikyū, Daegu, South Korea
  • 2012
    • Chi-Mei Medical Center
      臺南市, Taiwan, Taiwan
    • Kyung Hee University
      Sŏul, Seoul, South Korea
  • 2006-2011
    • Yonsei University
      • Department of Neurosurgery
      Sŏul, Seoul, South Korea
  • 2006-2007
    • Hankyong National University
      • Genomic Information Center
      Anjŏ, Gyeonggi-do, South Korea
  • 2005-2007
    • National Institute of Ecology
      Songhae, Gyeonggi-do, South Korea
  • 2003-2006
    • Yonsei University Hospital
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
  • 1999-2005
    • Seoul National University
      Sŏul, Seoul, South Korea
  • 2004
    • Chungnam National University
      Daiden, Daejeon, South Korea
  • 2000
    • University of Suwon
      Suigen, Gyeonggi Province, South Korea
  • 1996
    • Iwate University
      • Faculty of Engineering
      Morioka, Iwate, Japan
  • 1994-1995
    • Tohoku University
      • Institute for Materials Research
      Japan